Toronto Dominion Bank Has $227,000 Stake in Tilray Inc (NASDAQ:TLRY)

Toronto Dominion Bank increased its position in Tilray Inc (NASDAQ:TLRY) by 454.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 128,923 shares of the company’s stock after purchasing an additional 105,671 shares during the quarter. Toronto Dominion Bank’s holdings in Tilray were worth $227,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. BNP Paribas Financial Markets lifted its holdings in shares of Tilray by 1,314.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,819,494 shares of the company’s stock worth $3,202,000 after acquiring an additional 1,690,827 shares during the period. Point72 Asset Management L.P. bought a new position in Tilray during the third quarter worth about $1,348,000. Bank of Montreal Can boosted its holdings in Tilray by 19.6% during the second quarter. Bank of Montreal Can now owns 2,169,100 shares of the company’s stock valued at $3,622,000 after purchasing an additional 355,778 shares in the last quarter. Creative Planning grew its stake in shares of Tilray by 36.6% in the 3rd quarter. Creative Planning now owns 141,921 shares of the company’s stock valued at $250,000 after purchasing an additional 38,054 shares during the period. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Tilray by 11.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 682,478 shares of the company’s stock worth $1,131,000 after buying an additional 70,605 shares in the last quarter. Institutional investors and hedge funds own 9.35% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Roth Mkm decreased their price target on Tilray from $2.00 to $1.75 and set a “neutral” rating on the stock in a research note on Friday, October 11th.

Tilray Price Performance

NASDAQ:TLRY opened at $1.20 on Tuesday. The company has a quick ratio of 1.57, a current ratio of 2.47 and a debt-to-equity ratio of 0.08. The firm has a market cap of $1.08 billion, a PE ratio of -4.44 and a beta of 2.08. Tilray Inc has a 12 month low of $1.15 and a 12 month high of $2.97. The company’s 50-day moving average price is $1.48 and its two-hundred day moving average price is $1.67.

Tilray (NASDAQ:TLRY) last announced its earnings results on Thursday, October 10th. The company reported ($0.04) EPS for the quarter, hitting the consensus estimate of ($0.04). Tilray had a negative return on equity of 2.00% and a negative net margin of 26.79%. The business had revenue of $200.00 million for the quarter, compared to the consensus estimate of $218.70 million. During the same period in the previous year, the business earned ($0.10) EPS. Tilray’s revenue was up 13.0% compared to the same quarter last year. On average, equities analysts anticipate that Tilray Inc will post -0.14 EPS for the current fiscal year.

Insider Transactions at Tilray

In related news, CFO Carl A. Merton bought 26,000 shares of Tilray stock in a transaction dated Friday, November 15th. The shares were bought at an average cost of $1.36 per share, for a total transaction of $35,360.00. Following the completion of the transaction, the chief financial officer now owns 26,000 shares of the company’s stock, valued at approximately $35,360. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 0.87% of the company’s stock.

Tilray Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.